NUCALA Drug Insight and Market Forecast - 2032

“NUCALA Drug Insight and Market Forecast - 2032” report provides comprehensive insights about NUCALA for Nasal Polyposis in the 7MM. A detailed picture of the NUCALA for Nasal Polyposis in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019-2032 is provided in this report along with a detailed description of the NUCALA for Nasal Polyposis. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the NUCALA market forecast, analysis for Nasal Polyposis in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about emerging therapies in Nasal Polyposis.

Drug Summary

GSK's NUCALA (Mepolizumab) is the first IL-5 therapy approved as an add-on treatment in the US for adults with chronic rhinosinusitis with nasal polyps to target eosinophilic inflammation in adult patients 18 years of age and older with inadequate response to nasal corticosteroids. NUCALA got recently approved by US FDA based on positive results from the pivotal Synapse study.

Mepolizumab is also approved for use in three other eosinophilic driven diseases, the first indication being for patients with severe eosinophilic asthma aged 6 years and older. Additionally, mepolizumab was the first biologic therapy indicated for adults with eosinophilic granulomatosis with polyangiitis (EGPA) and also the first biologic to be approved for patients aged 12 years and older with hypereosinophilic syndrome (HES) (FDA, 2021). After the approval for CRSwNP, NUCALA has become the only treatment approved in the US for use in four eosinophil-driven diseases. NUCALA has contributed to giving one of the broadest portfolios to GSK in respiratory medicines (GSK, 2020)
Mepolizumab is an IL-5 antagonist (IgG1 kappa). IL-5 is the major cytokine responsible for the growth and differentiation, recruitment, activation, and survival of eosinophils. Mepolizumab binds to IL-5 with a dissociation constant of 100 pM, inhibiting the bioactivity of IL-5 by blocking its binding to the alpha chain of the IL-5 receptor complex expressed on the eosinophil cell surface. Inflammation is an important component in the pathogenesis of asthma, CRSwNP, EGPA, and HES. Multiple cell types (e.g., mast cells, eosinophils, neutrophils, macrophages, lymphocytes) and mediators (e.g., histamine, eicosanoids, leukotrienes, and cytokines) are involved in inflammation. By inhibiting IL-5 signaling, Mepolizumab reduces the production and survival of eosinophils; however, the mechanism of mepolizumab action in asthma, CRSwNP, EGPA, and HES has not been definitively established.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the NUCALA description, mechanism of action, dosage and administration, research and development activities in Nasal Polyposis.
• Elaborated details on NUCALA regulatory milestones and other development activities have been provided in this report.
• The report also highlights the NUCALA research and development activity in Nasal Polyposis details across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around NUCALA.
• The report contains forecasted sales of NUCALA for Nasal Polyposis till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Nasal Polyposis.
• The report also features the SWOT analysis with analyst views for NUCALA in Nasal Polyposis.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by a team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

NUCALA Analytical Perspective

In-depth NUCALA Market Assessment

This report provides a detailed market assessment of NUCALA in Nasal Polyposis in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2022 to 2032.

NUCALA Clinical Assessment

The report provides the clinical trials information of NUCALA for Nasal Polyposis covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for Nasal Polyposis is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence NUCALA dominance.
• Other emerging products for Nasal Polyposis are expected to give tough market competition to NUCALA and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of NUCALA in Nasal Polyposis.
• Our in-depth analysis of the forecasted sales data of NUCALA from 2022 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the NUCALA in Nasal Polyposis.

 

Key Questions Answered

• What is the product type, route of administration and mechanism of action of NUCALA?
• What is the clinical trial status of the study related to NUCALA in Nasal Polyposis and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the NUCALA development?
• What are the key designations that have been granted to NUCALA for Nasal Polyposis?
• What is the forecasted market scenario of NUCALA for Nasal Polyposis?
• What are the forecasted sales of NUCALA in the 7MM, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available in Nasal Polyposis and how are they giving competition to NUCALA for Nasal Polyposis?
• Which are the late-stage emerging therapies under development for the treatment of Nasal Polyposis?